The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

The increasing popularity of weight loss drugs like Wegovy, Ozempic, Mounjaro and metformin may have you wondering how all these options stack up.

Novo Nordisk was previously sued in 2023, along with competitor Eli Lilly, by a patient with severe gastrointestinal side effects after taking Ozempic and Lily's Mounjaro.